Host-reactive T-lymphocyte (None)

Host-reactive T-lymphocytes are donor-derived immune cells that recognize and attack the recipient's tissues following an allogeneic transplant (Source: StatPearls). This recognition is primarily mediated by the T-cell receptor (TCR) interacting with host Major Histocompatibility Complex (MHC) molecules (Source: PubMed). These cells are the primary drivers of Graft-versus-Host Disease (GvHD), which can cause severe damage to the skin, liver, and gastrointestinal tract (Source: NIH). The term "third-party alloantigens" refers to antigens from a donor other than the patient or the primary stem cell source, often used in the context of off-the-shelf virus-specific T-cell (VST) therapies (Source: PubMed). In such therapies, it is crucial to ensure that the T cells do not exhibit host-reactivity to prevent GvHD, while their reactivity to third-party antigens may affect their persistence in the recipient (Source: Journal of Clinical Oncology). Therapeutic strategies targeting these cells include broad immunosuppression with calcineurin inhibitors like tacrolimus or cyclosporine (Source: PubChem). More selective approaches, such as photodynamic therapy or costimulation blockade with abatacept, aim to deplete or inhibit only the alloreactive clones (Source: PubMed). Monitoring these cells involves biomarkers like CD25 and HLA-DR, which indicate T-cell activation (Source: UniProt). A major challenge in targeting these cells is maintaining the beneficial graft-versus-leukemia effect while preventing systemic autoimmunity (Source: PubMed). Overall, managing host-reactive T-lymphocytes is a cornerstone of successful allogeneic transplantation and cellular immunotherapy.

Other names

Alloreactive T-lymphocyteHost-reactive T-cellAlloreactive T-cellGvHD effector cellDonor-derived host-reactive T-lymphocyte

Inhibition of T-cell activation, proliferation, and effector function through calcineurin inhibition, costimulation blockade, or direct depletion of the T-cell population.